31.99 USD
-0.89 (-2.71%)
AAPG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. AAPG has a bad profitability rating. Also its financial health evaluation is rather negative. AAPG is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AAPG has reported negative net income.
AAPG had a negative operating cash flow in the past year.
In the past 5 years AAPG always reported negative net income.
In the past 5 years AAPG always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -38.05%, AAPG is doing good in the industry, outperforming 60.64% of the companies in the same industry.
AAPG has a Return On Equity of -174.06%. This is in the lower half of the industry: AAPG underperforms 67.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.05% | ||
| ROE | -174.06% | ||
| ROIC | N/A |
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 90.87%, AAPG belongs to the top of the industry, outperforming 92.47% of the companies in the same industry.
In the last couple of years the Gross Margin of AAPG has grown nicely.
AAPG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
2. Health
2.1 Basic Checks
AAPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AAPG has more shares outstanding
The number of shares outstanding for AAPG has been increased compared to 5 years ago.
The debt/assets ratio for AAPG has been reduced compared to a year ago.
2.2 Solvency
AAPG has an Altman-Z score of 1.49. This is a bad value and indicates that AAPG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AAPG (1.49) is better than 63.84% of its industry peers.
A Debt/Equity ratio of 1.99 is on the high side and indicates that AAPG has dependencies on debt financing.
AAPG's Debt to Equity ratio of 1.99 is on the low side compared to the rest of the industry. AAPG is outperformed by 80.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.99 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.49 |
ROIC/WACCN/A
WACC6.92%
2.3 Liquidity
A Current Ratio of 1.54 indicates that AAPG should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.54, AAPG is doing worse than 81.92% of the companies in the same industry.
AAPG has a Quick Ratio of 1.53. This is a normal value and indicates that AAPG is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.53, AAPG is not doing good in the industry: 81.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.53 |
3. Growth
3.1 Past
AAPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -184.96%.
The Revenue for AAPG has decreased by -56.75% in the past year. This is quite bad
AAPG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 132.25% yearly.
EPS 1Y (TTM)-184.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-409.56%
Revenue 1Y (TTM)-56.75%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%-71.63%
3.2 Future
AAPG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.42% yearly.
AAPG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.38% yearly.
EPS Next Y-186.08%
EPS Next 2Y103.96%
EPS Next 3Y9.42%
EPS Next 5YN/A
Revenue Next Year-42.1%
Revenue Next 2Y64.73%
Revenue Next 3Y21.64%
Revenue Next 5Y24.38%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AAPG. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 25.96 indicates a quite expensive valuation of AAPG.
Based on the Price/Forward Earnings ratio, AAPG is valued cheaply inside the industry as 93.03% of the companies are valued more expensively.
AAPG's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.96 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.96%
EPS Next 3Y9.42%
5. Dividend
5.1 Amount
AAPG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AAPG (12/8/2025, 11:58:35 AM)
31.99
-0.89 (-2.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners9.3%
Inst Owner Change15.04%
Ins Owners12.74%
Ins Owner ChangeN/A
Market Cap2.97B
Revenue(TTM)390.60M
Net Income(TTM)-1.16B
Analysts86.15
Price Target39.73 (24.2%)
Short Float %0%
Short Ratio0.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.6%
PT rev (3m)-13.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-16.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.96 | ||
| P/S | 53.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 31.57 | ||
| P/tB | 36.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.84
EYN/A
EPS(NY)1.23
Fwd EY3.85%
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.59
BVpS1.01
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.05% | ||
| ROE | -174.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.87% | ||
| FCFM | N/A |
ROA(3y)-27.9%
ROA(5y)-29.89%
ROE(3y)-633.86%
ROE(5y)-409%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y2.55%
F-Score2
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.99 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 29.84% | ||
| Cap/Sales | 7.12% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.53 | ||
| Altman-Z | 1.49 |
F-Score2
WACC6.92%
ROIC/WACCN/A
Cap/Depr(3y)161.69%
Cap/Depr(5y)588.72%
Cap/Sales(3y)47.03%
Cap/Sales(5y)745.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-409.56%
EPS Next Y-186.08%
EPS Next 2Y103.96%
EPS Next 3Y9.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-56.75%
Revenue growth 3Y227.53%
Revenue growth 5Y132.25%
Sales Q2Q%-71.63%
Revenue Next Year-42.1%
Revenue Next 2Y64.73%
Revenue Next 3Y21.64%
Revenue Next 5Y24.38%
EBIT growth 1Y-249.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-258.42%
EBIT Next 3Y-28.37%
EBIT Next 5YN/A
FCF growth 1Y73.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.48%
OCF growth 3YN/A
OCF growth 5YN/A
ASCENTAGE PHARMA GR-ADR / AAPG FAQ
What is the fundamental rating for AAPG stock?
ChartMill assigns a fundamental rating of 2 / 10 to AAPG.
Can you provide the valuation status for ASCENTAGE PHARMA GR-ADR?
ChartMill assigns a valuation rating of 1 / 10 to ASCENTAGE PHARMA GR-ADR (AAPG). This can be considered as Overvalued.
Can you provide the profitability details for ASCENTAGE PHARMA GR-ADR?
ASCENTAGE PHARMA GR-ADR (AAPG) has a profitability rating of 2 / 10.
Can you provide the financial health for AAPG stock?
The financial health rating of ASCENTAGE PHARMA GR-ADR (AAPG) is 2 / 10.